The Brains Behind SGLT2 Inhibition

Diabetes Care. 2022 Feb 1;45(2):273-275. doi: 10.2337/dci21-0050.

Authors

Haiko Schlögl^{1

2}, Michael Stumvoll¹

Affiliations

¹ Division of Endocrinology, Department of Endocrinology, Nephrology, Rheumatology, University Hospital Leipzig, Leipzig, Germany.
² Helmholtz Institute for Metabolic, Obesity, and Vascular Research (HI-MAG), Helmholtz Zentrum München, University of Leipzig and the University Hospital Leipzig, Leipzig, Germany.

PMID: 35050363
DOI: 10.2337/dci21-0050

No abstract available

Publication types

Comment

MeSH terms

Brain
Diabetic Nephropathies*
Humans
Sodium-Glucose Transporter 2 / metabolism
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors